Here’s a study from Israel (full pdf) looking at reinfections across three groups:
- vaccinated (Pfizer) and no previous infection
- non-vaccinated and confirmed previous infection
- vaccinated and confirmed previous infection
The study looks at the time period where the Delta variant was dominant in Israel.
This is the largest real-world observational study comparing natural immunity, gained
through previous SARS-CoV-2 infection, to vaccine-induced immunity, afforded by
the BNT162b2 mRNA vaccine.
Results
SARS-CoV-2-naïve vaccinees had a 13.06-fold (95% CI, 8.08 to 21.11) increased risk
for breakthrough infection with the Delta variant compared to those previously
infected, when the first event (infection or vaccination) occurred during January and
February of 2021. The increased risk was significant (P<0.001) for symptomatic
disease as well. When allowing the infection to occur at any time before vaccination
(from March 2020 to February 2021), evidence of waning natural immunity was
demonstrated, though SARS-CoV-2 naïve vaccinees had a 5.96-fold (95% CI, 4.85 to 7.33) increased risk for breakthrough infection and a 7.13-fold (95% CI, 5.51 to 9.21)
increased risk for symptomatic disease. SARS-CoV-2-naïve vaccinees were also at a
greater risk for COVID-19-related-hospitalizations compared to those that were
previously infected.
Some of the raw numbers:
46,035 persons in each of the groups (previously infected vs.
vaccinated
When comparing the vaccinated individuals to those previously infected at any time
(including during 2020), we found that throughout the follow-up period, 748 cases of
SARS-CoV-2 infection were recorded, 640 of which were in the vaccinated group
(breakthrough infections) and 108 in the previously infected group (reinfections)
552 symptomatic cases of SARS-CoV-2 were recorded, 484 in the vaccinated group and 68 in the previously infected group
COVID-19 related hospitalizations occurred in 21 and 4 of the breakthrough infection and reinfection groups, respectively
No COVID-19-related deaths were recorded
Conclusions
This study demonstrated that natural immunity confers longer lasting and stronger protection against infection, symptomatic disease and hospitalization caused by the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity. Individuals who were both previously infected with SARS-CoV-2 and given a single dose of the vaccine gained additional protection against the Delta variant.
My thoughts: This is absolutely fantastic news. The vaccines are outstanding, and strong natural immunity takes nothing away from that. We should all be hoping for strong and lasting natural immunity, especially given the number of natural infections out there.